Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15011822 | 0.88 | AR (0.35) | ARTAS2R14TSHRSMN1; SMN2LIPE | |
| SCHEMBL29593037 | 0.82 | TAS2R14 (0.34) | ARTAS2R14TSHRSMN1; SMN2CYP2D6 | |
| SCHEMBL13868349 | 0.80 | KIF11 (0.33) | LIPEKIF11 | |
| SCHEMBL2645798 | 0.80 | LPL (0.44) | AR | |
| SCHEMBL29929462 | 0.80 | LPL (0.44) | AR | |
| SCHEMBL44941 | 0.80 | ALDH1A1 (0.38) | TSHRLIPENOS2 | |
| SCHEMBL30990845 | 0.80 | ALDH1A1 (0.38) | TSHRLIPENOS2 | |
| SCHEMBL18230306 | 0.78 | AR (0.34) | AR | |
| SCHEMBL26129832 | 0.78 | ESR2 (0.33) | AR | |
| SCHEMBL12542099 | 0.78 | LIPE (0.39) | TAS2R14LIPEKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| US-9376436-B2 | 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators | Convergence Pharmaceuticals Limited (GB) | 2016-06-28 | — | — | US | disclosed |
| EP-2794612-B1 | 2-(PYRIDIN-2YL)-1,7-DIAZA-SPIRO[4.4]NONANE-6-ONE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2015-08-13 | — | — | US | disclosed |
| EP-2794612-A1 | 2 - (PYRIDIN- 2YL) - 1, 7 -DIAZA- SPIRO [4.4]NONANE- 6 -ONE COMPOUNDS AS VOLTAGE - GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093497-A1 | 2 - (PYRIDIN- 2YL) - 1, 7 -DIAZA- SPIRO [4.4] NONANE- 6 -ONE COMPOUNDS AS VOLTAGE - GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | AR 3185/4885TAS2R14 1906/4885TSHR 4658/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | AR 3185/4885TAS2R14 1906/4885TSHR 4658/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | AR 3185/4885TAS2R14 1906/4885TSHR 4658/4885 |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | SCN1A, SCN2A, SCN1B | AR 2497/4885TAS2R14 738/4885TSHR 1728/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | AR 3185/4885TAS2R14 1906/4885TSHR 4658/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | AR 3185/4885TAS2R14 1906/4885TSHR 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.